RxDoctor Payments Data

Brad Friedmann, DO

Family Medicine · Langhorne, PANPI 1922019363

Payments from drug & device makers

$11,718in general payments, 2019–2025

Across 722 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • GSK$1K
  • Pfizer$1K
  • Lilly USA, LLC$968
  • Amgen$754
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$11,55099%
  • Education$1671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,718 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$112,099
Medicare patients
309
Services billed
987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban82$81,950
OzempicSemaglutide54$69,094
TrulicityDulaglutide47$62,840
FarxigaDapagliflozin Propanediol44$43,135
JardianceEmpagliflozin32$40,172
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$34,025
RybelsusSemaglutide17$32,634
XareltoRivaroxaban30$28,119
WegovySemaglutide18$24,991
MounjaroTirzepatide24$24,305
JanuviaSitagliptin Phosphate15$24,000
MyrbetriqMirabegron19$23,864
JanumetSitagliptin Phos/Metformin Hcl17$19,626
LinzessLinaclotide30$18,536
Tresiba Flextouch U-200Insulin Degludec14$16,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$1,430$126,71889 claims
Lilly USA, LLCTrulicity, Mounjaro$968$87,14671 claims
PfizerEliquis$1,027$81,95082 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,048$50,08171 claims
MerckJanuvia, Janumet$547$43,62532 claims
AstraZenecaFarxiga$619$43,13544 claims
Boehringer IngelheimJardiance$400$40,17232 claims
AbbVieLinzess, Restasis, Synthroid$1,131$31,15881 claims
Johnson & JohnsonXarelto$298$28,11930 claims
Astellas Pharma US IncMyrbetriq$109$23,86419 claims
Clarus Therapeutics Inc.Jatenzo$76$12,19511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →